BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD9793 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD9793\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06795022-11176@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:AZD9793: Phase 1/2 readout est. (NCT06795022)
DESCRIPTION:AZD9793\, phase 1/2.\nStudy: First in Human Study to Evaluate A
 ZD9793 in Participants With Advanced or Metastatic Solid Tumours\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/azd9793#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06795022
URL:https://assetmemo.bio/drug/azd9793#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
